A Dose-Escalation Study to Evaluate the Efficacy and Safety of Andexanet Alfa on Systemic Coagulation Profiles in Healthy Volunteers Following Factor Xa Inhibitor Administration

The primary objective is to evaluate the efficacy and pharmacodynamics of varying doses of andexanet alfa in healthy adults following the administration of a factor Xa inhibitor. This assessment is clinically significant for determining the dose-dependent impact of the agent on systemic blood clotting mechanisms. There are no secondary objectives reported.

This study involves a total of 78 healthy volunteers. The participant population includes both males and females. The cohort consists of individuals within the age range of 18 to 30 years. Vulnerable populations are included in the study group.

This Phase 3 clinical trial utilizes a study design to evaluate the efficacy and systemic effects of varying doses of andexanet alfa on blood clotting in healthy adults previously administered an FXa inhibitor. The research methodology involves a sequence of scheduled procedures, beginning with a screening visit to determine eligibility. Subsequent follow-up visits are conducted to monitor physiological responses, concluding with an end-of-study visit. The total duration of participant involvement is determined by the clinical protocol, although certain conditions may necessitate early termination from the study. The study focuses on assessing how different dosage levels influence coagulation parameters throughout the body.

The assessment of efficacy in this Phase 3 clinical trial is not specified in the provided documentation.